Oncotab, Inc. — Department of Health and Human Services SBIR Phase I: NCI

Description

OncoTab proposes to develop a targeted radionuclide therapy using its patented tumor specific antibody designated TAB for Triple Negative Breast Cancers The tumor specific nature of tihs newly discovered antibody makes this an ideal molecule for targeted radiotherapy applications both for TNBC patients and eventually in patients with other types of malignancies that express this MUC variant We propose to fully humanize this antibody and use innovative techniques developed by investigators at Duke Drs Vaidyanathan and Zalutsky to test the feasibility of labeling TAB with radioiodine I b evaluate the binding affinity and internalization of I labeled TAB in retarding growth and reducing the size of TNBC tumors in mice Finally we propose to initiate preliminart toxivity studies The overarching goal of this Phase I proposal is to determine if TAB can be used for targeted radioimmunotherapy of TNBC Successful completion will lead to Phase II activities focused on scaling up manufacturing and IND enabling studies in consultation with the FDA for a fast track approval